510(k) clearance given to product for use in real-time surgery.
Ultrasound can now be used real-time during spinal surgery. The Food & Drug Administration announced Tuesday it has awarded 510(k) clearance to TDi™ for its SonoVision™ ultrasound platform.
According to a company statement, SonoVision™ is the first machine learning-enabled ultrasound platform designed for intraoperative access to the spine.
“With this clearance, TDi™ ushers in a new era of innovations related to soft tissue imaging in spine surgery and the beginning of a much broader trend of artificial intelligence and machine learning being applied to satisfy challenging clinical requirements of spine surgery,” said Alex Kulianov, TDi™ chairman and chief executive officer.
SonoVision™ uses image-processing algorithms to differentiate between nerve, muscle, bone, and vessels during real-time. With FDA clearance, Kulianov said, it can be used as an imaging modality for spine surgery. Work is currently being done to develop expanded procedural applications, such as posterior access to the spine, 3D imaging, and image-guided navigation integration.
According to TDi™ officials, SonoVision™ will accelerate commercialization efforts in 2020.
Multicenter Study Shows Merits of AI-Powered Ultrasound Assessment for Detecting Ovarian Cancer
January 3rd 2025Adjunctive AI offered greater than seven percent increases in sensitivity, specificity, and accuracy for ultrasound detection of ovarian cancer in comparison to unassisted clinicians who lacked ultrasound expertise, according to findings from new international multicenter research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.